TIGeR-PaC is Enrolling Patients
The Phase III TIGeR-PaC clinical trial is currently enrolling unresectable locally advanced pancreatic cancer patients. TIGeR-PaC is a randomized study of RenovoRx’s Trans-Arterial Micro-Perfusion (RenovoTAMP) versus systemic chemotherapy. The goal of the trial is to prove extended median survival and improved quality of life through targeted delivery of therapy.
Unlike other treatments that are given systemically or intravenously (IV), with RenovoTAMP, the chemotherapy is delivered directly into the pancreas via the arteries closest to the tumor. This innovative therapy utilizes RenovoRx’s lead product candidate, RenovoGem (intra-arterial gemcitabine delivered in combination with FDA-cleared and patented RenovoCath delivery system).* There is evidence that suggests delivering chemotherapy via an artery close to the tumor is an effective method for shrinking or stabilizing certain types of cancer.**
In RenovoRx’s Phase I/II study, chemotherapy delivered directly via the RenovoTAMP procedure was associated with more than half the patients living over two years.** TIGeR-PaC, which currently has approximately 30 active clinical sites, is ultimately expected to involve 200 participants in the US and Europe.
Phase II/III clinical trial in development investigating RenovoTAMP for the treatment of Hilar Cholangiocarcinoma (HCCA) patients.
* RenovoTAMP is additionally compatible with other small molecule chemotherapy drugs
** Rosemurgy, Alexander, et. al. Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma, Journal of Pancreatic Cancer; Vol. 3, issue 1.